Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
LKB1 loss exhibited a dramatic reduction on tumor burden and metastatic potential; in particular, OVCAR8-STK11KO tumors had evidence of extensive necrosis, apoptosis and hypoxia.
|
31744879 |
2020 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The signaling pathway activated by metformin (LKB1/AMPK/mTOR) is implicated in tumor suppression in ApcMin/+ mice via metformin-induced reduction in polyp burden, increased ratio of pAMPK/AMPK, decreased pmTOR/mTOR ratio, and decreased pS6Ser235/S6Ser235 ratio in polyps.
|
31818851 |
2020 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We created and phenotyped mouse models in which mutations in <i>Kras</i> and in the tumour suppressor gene liver kinase B1 (<i>Lkb1</i>/<i>Stk11</i>) are conditionally induced in pancreatic ducts using Cre-mediated gene recombination.
|
31154393 |
2020 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Importantly, the lack of effect in cells expressing wild-type LKB1, predicts that treatment of LKB1 mutated tumors with ERK inhibitors should have a favorable toxicity profile.
|
31634668 |
2020 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Detailed phenotyping including tumor IHC and its correlation with comprehensive STK11 genotyping by full gene sequencing followed by large genomic rearrangement analysis was performed in an Indian PJS cohort.
|
30689838 |
2019 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
None of STK11 mutated tumors (n = 7) expressed PD-L1.
|
30885341 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The kinase LKB1 is a critical tumor suppressor in sporadic and familial human cancers, yet the mechanisms by which it suppresses tumor growth remain poorly understood.
|
31350327 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Liver kinase B1 (LKB1) is a newly discovered tumor suppressor gene that plays a role in apoptosis induction.
|
30863111 |
2019 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Patients with LKB1 expression loss experienced significantly lower disease-free survival (DFS) (hazard ratio [HR], 1.287; 95% confidence interval [CI], 1.093 to 1.654; p=0.021) and overall survival (OS) (HR, 1.541; 95% CI, 1.197 to 1.932; p=0.002), compared to patients with LKB1 expressing expressing tumors.
|
30913862 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The canonical AMP-dependent mechanism of activation requires the upstream kinase LKB1, which was identified genetically to be a tumour suppressor.
|
31288625 |
2019 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
LKB1 expression was compared with tumour size, histological grade, axillary lymph node stage, ER, PgR, EGFR, HER2, HER3, HER4, BRCA1&2, p53, Ki67, Bcl2, Muc1, E-Cadherin, CD44, basal (CK5, CK5/6, CK14 and CK17) and luminal (CK7/8, CK18 and CK19) cytokeratins, MDM2 and MDM4, and correlated with long-term clinical outcome.
|
30696074 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Liver kinase B1 (LKB1), a tumor suppressor, is a central regulator of cell polarity and energy homeostasis.
|
30935996 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
According to our results, LCAL1 may physically interact with the catalytic subunit of tumor suppressor AMPK, prevent AMPK activation by upstream kinase (liver kinase B1), and thus inhibit the downstream AMPK signaling network.
|
30741368 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Liver kinase b1 (LKB1) is a tumor suppressor, and the inactivated mutation frequency of LKB1 in lung adenocarcinoma is ~20%.
|
31322182 |
2019 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
NGS showed that the medullary component of this tumor had a novel STK11 p.G270W mutation, which was not present in the mucinous component.
|
31243107 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Serine-threonine kinase11 (STK11) is a tumor suppressor gene which plays a key role in regulating cell growth and apoptosis.
|
31712642 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Finally, we provide evidence that endogenous LKB1 is modified by SUMO in pre-clinical mouse models of HCC and clinical HCC, where LKB1 SUMOylation is higher in fast growing tumors.
|
30594553 |
2019 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Inactivating mutations of the tumor suppressor gene Liver Kinase B1 (<i>LKB1</i>) are frequently detected in non-small-cell lung cancer (NSCLC) and cervical carcinoma.
|
31781355 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The tumor suppressor liver kinase B1 (LKB1) was revealed to be a potential target of miR-744, suggesting its potential mechanism of action.
|
30675291 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Co-occurring genomic alterations, particularly in tumour suppressor genes such as TP53 and LKB1 (also known as STK11), have emerged as core determinants of the molecular and clinical heterogeneity of oncogene-driven lung cancer subgroups through their effects on both tumour cell-intrinsic and non-cell-autonomous cancer hallmarks.
|
31406302 |
2019 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Low LKB1 expression predicts shorter OS, worse tumour differentiation, larger tumours, earlier lymph node metastasis and more advanced TNM stage.
|
31383697 |
2019 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
STK11 gene mutations may provide insights in the development of multiple cartilaginous tumors in enchondromatosis, this tumor suppressor gene having been shown in animal models to regulate both chondrocyte maturation and growth plate organization during development.
|
31240473 |
2019 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Mutations in the LKB1 (also known as <i>STK11</i>) tumor suppressor are the third most frequent genetic alteration in non-small cell lung cancer (NSCLC).
|
31350328 |
2019 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Thus, this study reveals HPD as a novel regulator of LKB1-AMPK signaling-mediated HDAC10 nuclear location, which contributes to G6PD expression in promoting tumor growth, which is a promising target for lung cancer treatment.
|
31285420 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Liver kinase B1 (LKB1) is a tumor suppressor that functions as master regulator of cell growth, metabolism, survival, and polarity.
|
31513784 |
2019 |